Clinical Trials Update: May 26, 2006
Lymphomas Alzheimer's Disease Genital Herpes
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
This trial will evaluate AMG 531 to treat chemotherapy induced thrombocytopenia (CIT) in people with aggressive lymphoma. Volunteers diagnosed with aggressive Hodgkin's lymphoma or aggressive Non-Hodgkin's lymphoma who have adequate bone marrow and liver function and no more that one prior relapse chemotherapy regimen may qualify.
The research site is in New York City.
This trial is evaluating the investigational agent MPC-7869 (Flurizan, R-flurbiprofen) to treat Alzheimer's disease. People with mild Alzheimer's, aged 55 or older with a caregiver, may qualify. Participants will be able to continue their current Alzheimer's treatment. Eligible volunteers will receive study related evaluations, lab tests, and study medication or placebo at no cost, and may be compensated up to $700 for time and travel.
The research site is in La Jolla, Calif.
This study will evaluate famciclovir given twice daily for one day compared to valacyclovir given twice daily for three days to treat genital herpes. Candidates 18 and older who have had at least four genital herpes outbreaks in the preceding 12 months and are not pregnant or breast feeding may be eligible.
Research sites are located throughout the United States.
Copyright 2006 CenterWatch. All rights reserved.